194 related articles for article (PubMed ID: 36494680)
1. MYBL2 regulates de novo purine synthesis by transcriptionally activating IMPDH1 in hepatocellular carcinoma cells.
Zhao JZ; Wang W; Liu T; Zhang L; Lin DZ; Yao JY; Peng X; Jin G; Ma TT; Gao JB; Huang F; Nie J; Lv Q
BMC Cancer; 2022 Dec; 22(1):1290. PubMed ID: 36494680
[TBL] [Abstract][Full Text] [Related]
2. Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype.
Frau M; Ladu S; Calvisi DF; Simile MM; Bonelli P; Daino L; Tomasi ML; Seddaiu MA; Feo F; Pascale RM
J Hepatol; 2011 Jul; 55(1):111-9. PubMed ID: 21419759
[TBL] [Abstract][Full Text] [Related]
3. Inosine monophosphate dehydrogenase type1 sustains tumor growth in hepatocellular carcinoma.
Jia X; Liu Y; Cheng Y; Wang Y; Kang H; Ma Z; Chen K
J Clin Lab Anal; 2022 May; 36(5):e24416. PubMed ID: 35403278
[TBL] [Abstract][Full Text] [Related]
4. MYB proto-oncogene like 2 promotes hepatocellular carcinoma growth and glycolysis via binding to the
Liu M; Du Q; Mao G; Dai N; Zhang F
Bioengineered; 2022 Mar; 13(3):5344-5356. PubMed ID: 35176941
[TBL] [Abstract][Full Text] [Related]
5. LncRNA UCA1 Participates in De Novo Synthesis of Guanine Nucleotides in Bladder Cancer by Recruiting TWIST1 to Increase IMPDH1/2.
Liu SS; Li JS; Xue M; Wu WJ; Li X; Chen W
Int J Biol Sci; 2023; 19(8):2599-2612. PubMed ID: 37215997
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA LINC01139 promotes the progression of hepatocellular carcinoma by upregulating MYBL2 via competitively binding to miR-30 family.
Li ZB; Chu HT; Jia M; Li L
Biochem Biophys Res Commun; 2020 May; 525(3):581-588. PubMed ID: 32115147
[TBL] [Abstract][Full Text] [Related]
7. Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53.
Calvisi DF; Simile MM; Ladu S; Frau M; Evert M; Tomasi ML; Demartis MI; Daino L; Seddaiu MA; Brozzetti S; Feo F; Pascale RM
Hepatology; 2011 Apr; 53(4):1226-36. PubMed ID: 21480327
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of MYBL2 predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.
Le L; Luo J; Wu H; Chen L; Tang X; Fu F
Eur J Histochem; 2021 Mar; 65(2):. PubMed ID: 33782625
[TBL] [Abstract][Full Text] [Related]
9. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
10. Actin-binding Rho activating C-terminal like (ABRACL) transcriptionally regulated by MYB proto-oncogene like 2 (MYBL2) promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of breast cancer cells.
Li J; Chen H
Bioengineered; 2022 Apr; 13(4):9019-9031. PubMed ID: 35341461
[TBL] [Abstract][Full Text] [Related]
11. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
Liu C; Zhang W; Zhou X; Liu L
Front Immunol; 2022; 13():983490. PubMed ID: 36618420
[TBL] [Abstract][Full Text] [Related]
12. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
Ma F; Zhu Y; Liu X; Zhou Q; Hong X; Qu C; Feng X; Zhang Y; Ding Q; Zhao J; Hou J; Zhong M; Zhuo H; Zhong L; Ye Z; Xie W; Liu Y; Xiong Y; Chen H; Piao D; Sun B; Gao Z; Li Q; Zhang Z; Qiu X; Zhang Z
Hepatology; 2019 Nov; 70(5):1785-1803. PubMed ID: 31066068
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of MYBL2 promotes proliferation and migration of non-small-cell lung cancer via upregulating NCAPH.
Xiong YC; Wang J; Cheng Y; Zhang XY; Ye XQ
Mol Cell Biochem; 2020 May; 468(1-2):185-193. PubMed ID: 32200471
[TBL] [Abstract][Full Text] [Related]
14. c-Myc-IMPDH1/2 axis promotes tumourigenesis by regulating GTP metabolic reprogramming.
Zhang Q; Cui K; Yang X; He Q; Yu J; Yang L; Yao G; Guo W; Luo Z; Liu Y; Chen Y; He Z; Lan P
Clin Transl Med; 2023 Jan; 13(1):e1164. PubMed ID: 36629054
[TBL] [Abstract][Full Text] [Related]
15. Purine anabolism creates therapeutic vulnerability in hepatocellular carcinoma through m 6 A-mediated epitranscriptomic regulation.
Hung MH; Chang CW; Wang KC; Chaisaingmongkol J; Ruchirawat M; Greten TF; Wang XW
Hepatology; 2023 Nov; 78(5):1462-1477. PubMed ID: 37094826
[TBL] [Abstract][Full Text] [Related]
16. The critical role of dysregulated Hh-FOXM1-TPX2 signaling in human hepatocellular carcinoma cell proliferation.
Wang Y; Wang H; Yan Z; Li G; Hu G; Zhang H; Huang D; Wang Y; Zhang X; Yan Y; Lu Q; Cheng M; Luo S
Cell Commun Signal; 2020 Jul; 18(1):116. PubMed ID: 32723329
[TBL] [Abstract][Full Text] [Related]
17. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial transcriptional regulation of HEB/ZEB1/ASCL1 and MYBL2 on Ras/ErbB signaling.
Zhong F; Chen T; Li B
Biochem Biophys Res Commun; 2022 Sep; 622():170-176. PubMed ID: 35932528
[TBL] [Abstract][Full Text] [Related]
19. Yin Yang 1-mediated epigenetic silencing of tumour-suppressive microRNAs activates nuclear factor-κB in hepatocellular carcinoma.
Tsang DP; Wu WK; Kang W; Lee YY; Wu F; Yu Z; Xiong L; Chan AW; Tong JH; Yang W; Li MS; Lau SS; Li X; Lee SD; Yang Y; Lai PB; Yu DY; Xu G; Lo KW; Chan MT; Wang H; Lee TL; Yu J; Wong N; Yip KY; To KF; Cheng AS
J Pathol; 2016 Apr; 238(5):651-64. PubMed ID: 26800240
[TBL] [Abstract][Full Text] [Related]
20. Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling.
Li M; Jin C; Xu M; Zhou L; Li D; Yin Y
Cell Commun Signal; 2017 Dec; 15(1):52. PubMed ID: 29246230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
